ECSP22012826A - Inhibidores de parp1 - Google Patents
Inhibidores de parp1Info
- Publication number
- ECSP22012826A ECSP22012826A ECSENADI202212826A ECDI202212826A ECSP22012826A EC SP22012826 A ECSP22012826 A EC SP22012826A EC SENADI202212826 A ECSENADI202212826 A EC SENADI202212826A EC DI202212826 A ECDI202212826 A EC DI202212826A EC SP22012826 A ECSP22012826 A EC SP22012826A
- Authority
- EC
- Ecuador
- Prior art keywords
- parp1 inhibitors
- parp1
- inhibitors
- formula
- medicine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de azaquinolona de fórmula (I), y a su uso en medicina. Fórmula (I)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876065P | 2019-07-19 | 2019-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22012826A true ECSP22012826A (es) | 2022-03-31 |
Family
ID=71728735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202212826A ECSP22012826A (es) | 2019-07-19 | 2022-02-17 | Inhibidores de parp1 |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US11325906B2 (es) |
| EP (2) | EP4529952A3 (es) |
| JP (1) | JP7641944B2 (es) |
| KR (1) | KR102929356B1 (es) |
| CN (1) | CN114144413B (es) |
| AR (1) | AR119424A1 (es) |
| AU (1) | AU2020318599B2 (es) |
| BR (1) | BR112022000534A2 (es) |
| CA (1) | CA3145644A1 (es) |
| CL (1) | CL2022000110A1 (es) |
| CO (1) | CO2022001590A2 (es) |
| CR (1) | CR20220070A (es) |
| DK (1) | DK3999506T3 (es) |
| DO (1) | DOP2022000006A (es) |
| EC (1) | ECSP22012826A (es) |
| ES (1) | ES3021859T3 (es) |
| FI (1) | FI3999506T3 (es) |
| HR (1) | HRP20250373T1 (es) |
| HU (1) | HUE071067T2 (es) |
| IL (1) | IL289534B2 (es) |
| JO (1) | JOP20220008A1 (es) |
| LT (1) | LT3999506T (es) |
| MA (1) | MA57972B1 (es) |
| MX (1) | MX2022000711A (es) |
| MY (1) | MY208549A (es) |
| PE (1) | PE20221339A1 (es) |
| PH (1) | PH12022550098A1 (es) |
| PL (1) | PL3999506T3 (es) |
| PT (1) | PT3999506T (es) |
| RS (1) | RS66682B1 (es) |
| SI (1) | SI3999506T1 (es) |
| SM (1) | SMT202500146T1 (es) |
| TW (1) | TWI837403B (es) |
| UA (1) | UA129093C2 (es) |
| UY (1) | UY38793A (es) |
| WO (1) | WO2021013735A1 (es) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| TWI837403B (zh) | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN116783181B (zh) * | 2021-04-12 | 2026-01-30 | 上海瑛派药业有限公司 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
| CN117177972A (zh) * | 2021-04-19 | 2023-12-05 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| WO2022222921A1 (zh) * | 2021-04-22 | 2022-10-27 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
| CN116710433B (zh) * | 2021-04-23 | 2026-05-05 | 康百达（四川）生物医药科技有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN116867783B (zh) * | 2021-04-23 | 2026-08-07 | 康百达（四川）生物医药科技有限公司 | 吡啶衍生物及其在医药上的应用 |
| CN116601148A (zh) * | 2021-04-23 | 2023-08-15 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| CN117321051A (zh) * | 2021-04-26 | 2023-12-29 | 重庆复尚源创医药技术有限公司 | 作为parp抑制剂的化合物 |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| AU2022276986B2 (en) * | 2021-05-18 | 2025-07-03 | Onconic Therapeutics Inc. | Parp inhibitor-resistant cancer therapeutic agent |
| AU2022280845A1 (en) * | 2021-05-24 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| CN115403595A (zh) * | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| JP2024522736A (ja) * | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用 |
| WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023036285A1 (zh) * | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023051812A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| WO2023051807A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| TWI876212B (zh) * | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| US20250222116A1 (en) * | 2021-10-22 | 2025-07-10 | Xizang Haisco Pharmaceutical Co., Ltd. | Parp-1 degradation agent and use thereof |
| AU2022392822B9 (en) * | 2021-11-18 | 2026-08-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CA3238572A1 (en) | 2021-11-19 | 2023-05-25 | Jing Zhang | Selective parp1 inhibitor and application thereof |
| WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CN118382624A (zh) * | 2021-12-17 | 2024-07-23 | 凯复(苏州)生物医药有限公司 | Parp抑制剂、包含其的药物组合物及其用途 |
| AU2022422276B2 (en) * | 2021-12-21 | 2025-12-11 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
| WO2023122140A1 (en) * | 2021-12-22 | 2023-06-29 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
| WO2023133413A1 (en) * | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| US20250221987A1 (en) * | 2022-01-13 | 2025-07-10 | Acerand Therapeutics (Hong Kong) Limited | Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CA3246093A1 (en) * | 2022-01-27 | 2023-08-03 | Xinthera, Inc. | PARP1 INHIBITORS AND THEIR USES |
| AU2023212785A1 (en) * | 2022-01-28 | 2024-08-15 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116693501B (zh) * | 2022-02-10 | 2025-12-19 | 康百达（四川）生物医药科技有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| WO2023165501A1 (zh) * | 2022-03-01 | 2023-09-07 | 杭州领业医药科技有限公司 | Azd5305的晶型及其制备方法和用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| CA3254948A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Polytherapy for the treatment of cancer |
| IL316019A (en) | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| AU2023250031A1 (en) * | 2022-04-07 | 2024-11-14 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| EP4514795A4 (en) * | 2022-04-28 | 2025-12-31 | Ningbo Newbay Tech Development Co Ltd | COMPOUNDS USED AS PARP1 INHIBITORS |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| KR20250023494A (ko) | 2022-06-15 | 2025-02-18 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| TW202408509A (zh) * | 2022-07-14 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 雜芳基衍生物的藥物組合物及其在醫藥上的應用 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| WO2024046420A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| CN118139862A (zh) * | 2022-09-30 | 2024-06-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| CN120035592A (zh) * | 2022-10-20 | 2025-05-23 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
| WO2024083201A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| US20260151378A1 (en) * | 2022-10-21 | 2026-06-04 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof |
| WO2024097775A1 (en) * | 2022-11-02 | 2024-05-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2024099386A1 (zh) * | 2022-11-10 | 2024-05-16 | 正大天晴药业集团股份有限公司 | 稠合双环化合物 |
| KR20250103773A (ko) | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
| CR20250267A (es) | 2022-12-06 | 2026-01-14 | Astrazeneca Ab | Inhibidores de polq |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| CN117903159A (zh) * | 2022-12-30 | 2024-04-19 | 成都硕德药业有限公司 | 一种内酰胺类衍生物、其制备方法及用途 |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| CN116396214B (zh) * | 2023-03-06 | 2026-03-31 | 爱斯特（成都）生物制药股份有限公司 | 一种parp1抑制剂中间体的制备方法 |
| US20240325384A1 (en) * | 2023-03-31 | 2024-10-03 | Astrazeneca Ab | Dosing regimen |
| JP2026513665A (ja) | 2023-03-31 | 2026-04-30 | アストラゼネカ・アクチエボラーグ | Ａｚｄ５３０５の投与レジメント |
| JP2026515235A (ja) | 2023-05-11 | 2026-05-14 | アストラゼネカ・アクチエボラーグ | 癌を治療するためのｐａｒｐ１阻害剤と選択的エストロゲン分解薬の併用 |
| JP2026517228A (ja) | 2023-05-17 | 2026-05-28 | テサロ， インコーポレイテッド | がんの治療におけるポリａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤の新規使用 |
| WO2024255782A1 (zh) | 2023-06-14 | 2024-12-19 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
| GB2630970A (en) * | 2023-06-15 | 2024-12-18 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| WO2024264072A2 (en) * | 2023-06-23 | 2024-12-26 | Stablix, Inc. | Parp inhibitors |
| AU2024316921A1 (en) | 2023-07-28 | 2026-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted nitrogen-containing bicyclic compound and use thereof |
| KR20260100685A (ko) | 2023-10-23 | 2026-06-30 | 길리애드 사이언시즈, 인코포레이티드 | Parp1 저해제 및 이의 용도 |
| WO2025092973A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Parp1靶向化合物及其用途 |
| AU2024394093A1 (en) | 2023-12-05 | 2026-06-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
| CN122555554A (zh) | 2024-01-19 | 2026-08-11 | 阿斯利康(瑞典)有限公司 | 包含azd5305的药物组合物 |
| CN120398887A (zh) * | 2024-01-31 | 2025-08-01 | 西藏海思科制药有限公司 | 一种双环衍生物parp抑制剂的晶型及其制备方法和应用 |
| WO2025168048A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海璎黎药业有限公司 | 一种三键结构化合物、其药物组合物及其应用 |
| KR20250128449A (ko) | 2024-02-20 | 2025-08-28 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| TW202608880A (zh) | 2024-05-31 | 2026-03-01 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
| WO2025261449A1 (zh) * | 2024-06-19 | 2025-12-26 | 浙江扬厉医药技术有限公司 | 一种parp1抑制剂吡啶酰胺类化合物、中间体及其制备方法 |
| KR20260019426A (ko) | 2024-08-01 | 2026-02-10 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| CN118978529A (zh) * | 2024-08-02 | 2024-11-19 | 上海信诺维生物医药有限公司 | 一类含吡啶的杂环化合物 |
| GB2703160A (en) * | 2024-12-09 | 2026-07-15 | Duke Street Bio Ltd | PARP1 Inhibitor Compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0699754B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Method for diagnosing a predisposition for breast and ovarian cancer |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| NZ546991A (en) | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| NZ546990A (en) * | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| JP4806353B2 (ja) | 2003-12-05 | 2011-11-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン |
| ES2565581T3 (es) | 2003-12-10 | 2016-04-05 | Janssen Pharmaceutica Nv | 2-Quinolinonas/2-quinoxalinonas 6-(hetero)ciclohexilalquil sustituidas como inhibidores de poli(ADP-ribosa) polimerasa |
| KR20070057859A (ko) | 2004-08-26 | 2007-06-07 | 쿠도스 파마슈티칼스 리미티드 | 4-헤테로아릴메틸 치환된 프탈라지논 유도체 |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| WO2009053373A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| EP2389379A1 (en) * | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| EP2415767B1 (en) * | 2009-03-27 | 2014-09-03 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) Polymerase (PARP) Inhibitors |
| US8541417B2 (en) * | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| JP2016522675A (ja) | 2013-03-14 | 2016-08-04 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター |
| TWI702046B (zh) | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| US10221156B2 (en) | 2015-07-08 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TWI837403B (zh) | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2020
- 2020-07-17 TW TW109124347A patent/TWI837403B/zh active
- 2020-07-17 CN CN202080051330.7A patent/CN114144413B/zh active Active
- 2020-07-17 FI FIEP20743121.4T patent/FI3999506T3/fi active
- 2020-07-17 EP EP25151532.6A patent/EP4529952A3/en active Pending
- 2020-07-17 CA CA3145644A patent/CA3145644A1/en active Pending
- 2020-07-17 MA MA57972A patent/MA57972B1/fr unknown
- 2020-07-17 HR HRP20250373TT patent/HRP20250373T1/hr unknown
- 2020-07-17 JO JOP/2022/0008A patent/JOP20220008A1/ar unknown
- 2020-07-17 MY MYPI2022000303A patent/MY208549A/en unknown
- 2020-07-17 LT LTEPPCT/EP2020/070306T patent/LT3999506T/lt unknown
- 2020-07-17 AR ARP200102008A patent/AR119424A1/es unknown
- 2020-07-17 DK DK20743121.4T patent/DK3999506T3/da active
- 2020-07-17 MX MX2022000711A patent/MX2022000711A/es unknown
- 2020-07-17 CR CR20220070A patent/CR20220070A/es unknown
- 2020-07-17 PL PL20743121.4T patent/PL3999506T3/pl unknown
- 2020-07-17 SI SI202030602T patent/SI3999506T1/sl unknown
- 2020-07-17 US US16/931,792 patent/US11325906B2/en active Active
- 2020-07-17 UA UAA202200512A patent/UA129093C2/uk unknown
- 2020-07-17 ES ES20743121T patent/ES3021859T3/es active Active
- 2020-07-17 PT PT207431214T patent/PT3999506T/pt unknown
- 2020-07-17 AU AU2020318599A patent/AU2020318599B2/en active Active
- 2020-07-17 EP EP20743121.4A patent/EP3999506B1/en active Active
- 2020-07-17 HU HUE20743121A patent/HUE071067T2/hu unknown
- 2020-07-17 BR BR112022000534A patent/BR112022000534A2/pt unknown
- 2020-07-17 SM SM20250146T patent/SMT202500146T1/it unknown
- 2020-07-17 RS RS20250332A patent/RS66682B1/sr unknown
- 2020-07-17 PH PH1/2022/550098A patent/PH12022550098A1/en unknown
- 2020-07-17 KR KR1020227005427A patent/KR102929356B1/ko active Active
- 2020-07-17 WO PCT/EP2020/070306 patent/WO2021013735A1/en not_active Ceased
- 2020-07-17 PE PE2022000086A patent/PE20221339A1/es unknown
- 2020-07-17 IL IL289534A patent/IL289534B2/en unknown
- 2020-07-17 JP JP2022502556A patent/JP7641944B2/ja active Active
- 2020-07-17 UY UY0001038793A patent/UY38793A/es active IP Right Grant
-
2022
- 2022-01-17 DO DO2022000006A patent/DOP2022000006A/es unknown
- 2022-01-17 CL CL2022000110A patent/CL2022000110A1/es unknown
- 2022-02-16 CO CONC2022/0001590A patent/CO2022001590A2/es unknown
- 2022-02-17 EC ECSENADI202212826A patent/ECSP22012826A/es unknown
- 2022-04-07 US US17/715,463 patent/US12606555B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001590A2 (es) | Inhibidores de parp1 | |
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| MX2022015435A (es) | Derivados de quinoxalina como farmacos anti-cancer. | |
| CL2019000477A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. | |
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| GEAP202215540A (en) | Pcsk9 antagonist compounds | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| MX2019007156A (es) | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. | |
| CL2018003527A1 (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
| EA201990615A1 (ru) | Пирролобензодиазепиновые конъюгаты | |
| NI201700034A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1. | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| BR112017002594A2 (pt) | compostos inibidores de cinase de ligação de tank | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| CY1123263T1 (el) | Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton | |
| MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
| MX382166B (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos. | |
| MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof |